MARKET

KPTI

KPTI

Karyopharm Therapeutics Inc
NASDAQ
1.801
+0.031
+1.75%
Opening 10:02 09/04 EDT
OPEN
1.770
PREV CLOSE
1.770
HIGH
1.805
LOW
1.755
VOLUME
111.97K
TURNOVER
--
52 WEEK HIGH
10.99
52 WEEK LOW
1.720
MARKET CAP
40.85M
P/E (TTM)
-0.1403
1D
5D
1M
3M
1Y
5Y
1D
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Aug 2026
Seeking Alpha · 2d ago
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), BioMarin Pharmaceutical (BMRN) and Karyopharm Therapeutics (KPTI)
TipRanks · 3d ago
Karyopharm Submits SNDA For XPOVIO Plus Ruxolitinib In Myelofibrosis; Stock Up
NASDAQ · 4d ago
Karyopharm Seeks Accelerated FDA Approval for XPOVIO Combo
TipRanks · 4d ago
Karyopharm Submits SNDA Seeking Accelerated Approval For XPOVIO In Combination With Ruxolitinib
NASDAQ · 4d ago
Karyopharm Therapeutics Submits sNDA To FDA Seeking Accelerated Approval For XPOVIO In Combination With Ruxolitinib For Patients With Myelofibrosis
Benzinga · 4d ago
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
PR Newswire · 4d ago
Weekly Report: what happened at KPTI last week (0824-0828)?
Weekly Report · 4d ago
More
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.

Webull offers Karyopharm Therapeutics Inc stock information, including NASDAQ: KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.